News & Updates
Filter by Specialty:
L-MOCA: Olaparib maintenance for ovarian cancer benefits Asians
Maintenance monotherapy with olaparib appears safe and effective in Asian patients with platinum-sensitive relapsed (PSR) ovarian cancer, regardless of their BRCA status, as shown in the results of the phase III, open-label, single-arm L-MOCA study.
L-MOCA: Olaparib maintenance for ovarian cancer benefits Asians
07 Jul 2022
RA patient’s perspective must be respected in treatment decisions, says study
Physician-reported measures on responses to tofacitinib and adalimumab treatments are higher than those reported by patients with rheumatoid arthritis (RA), according to a post hoc analysis of data from phase III and phase IIIb/IV trials.
RA patient’s perspective must be respected in treatment decisions, says study
07 Jul 2022
OSA prevalence similar between resistant, refractory hypertension
The prevalence of obstructive sleep apnoea (OSA) is similar between resistant and refractory hypertensive patients, a study has shown. However, those with refractory hypertension are usually younger and have a better sleep pattern.
OSA prevalence similar between resistant, refractory hypertension
07 Jul 2022
Post-transplant KRd a new SoC for MM?
In the ongoing phase III ATLAS study evaluating patients with newly diagnosed multiple myeloma (MM), progression-free survival (PFS) was better with maintenance treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) than lenalidomide (R) alone after autologous stem-cell transplantation (ASCT).
Post-transplant KRd a new SoC for MM?
07 Jul 2022
Catheter-directed thrombolysis trumps systemic anticoagulation for submassive pulmonary embolism
Catheter-directed thrombolysis (CDT) is superior to systemic anticoagulation (SA) for the treatment of submassive pulmonary embolism (sPE), leading to better mortality rates without additional safety signals, a recent meta-analysis has found.
Catheter-directed thrombolysis trumps systemic anticoagulation for submassive pulmonary embolism
07 Jul 2022
Diabetes status may influence long-term survival in metastatic breast cancer
Long-term overall survival (OS) in patients with metastatic breast cancer (MBC) may be influenced by diabetes status, according to a retrospective study presented at ENDO 2022.